2. Metabolic Enzyme/Protease NF-κB Immunology/Inflammation Apoptosis PI3K/Akt/mTOR Autophagy
  3. HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt Autophagy
  4. Deferoxamine

Deferoxamine  (Synonyms: 去铁胺; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine)

目录号: HY-B1625 纯度: 99.76%
COA 产品使用指南

摩尔计算器

Deferoxamine (Deferoxamine B) 是一种铁螯合剂 (结合 Fe(III) 和许多其他金属阳离子)，被广泛用于减少铁在组织中的积累和沉积。Deferoxamine 具有较好的抗氧化活性，可上调 HIF-1α 水平。Deferoxamine 还具有抗增殖活性，能诱导癌细胞凋亡和自噬。Deferoxamine 可用于糖尿病、神经退行性疾病以及抗癌和抗 COVID-19 的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Deferoxamine Chemical Structure

Deferoxamine Chemical Structure

CAS No. : 70-51-9

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥5316
In-stock
1 mg ￥3080
In-stock
5 mg ￥4310
In-stock
10 mg ￥5170
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Deferoxamine:

Deferoxamine 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 206 篇科研文献

IF
WB
Proliferation Assay
RT-PCR

    Deferoxamine purchased from MCE. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    The specific inhibitor of ferroptosis Fer-1 (100 μM) and Lip-1 (5 μM), and the iron chelator Deferoxamine (DFOM;100 μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24 h.

    Deferoxamine purchased from MCE. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    Deferoxamine (DFOM; 100 μM; 24 h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.

    Deferoxamine purchased from MCE. Usage Cited in: Sci Adv. 2022 Mar 4;8(9):eabm1896.  [Abstract]

    PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.

    Deferoxamine purchased from MCE. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.

    Deferoxamine purchased from MCE. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.

    Deferoxamine purchased from MCE. Usage Cited in: Acta Pharm Sin B. 2021 Jun;11(6):1513-1525.  [Abstract]

    Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.

    Deferoxamine purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2021 Mar 8;8(10):2004680.  [Abstract]

    Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.

    Deferoxamine purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20 μM; 48 h).

    Deferoxamine purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.

    Deferoxamine purchased from MCE. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20 nM; 24 h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).

    Deferoxamine purchased from MCE. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade

    Deferoxamine purchased from MCE. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded

    Deferoxamine purchased from MCE. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185.  [Abstract]

    The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.

    Deferoxamine purchased from MCE. Usage Cited in: ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6180-6189.  [Abstract]

    Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.

    查看 HIF/HIF Prolyl-Hydroxylase 亚型特异性产品:

    查看所有亚型
    HIF-1α HIF

    查看 Akt 亚型特异性产品:

    查看所有亚型
    Akt Akt1 Akt2 Akt3

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

    体外研究
    (In Vitro)

    Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1].
    Deferoxamine (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels[2].
    Deferoxamine (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs[3].
    Deferoxamine (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs[3].
    Deferoxamine (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs[3].
    Deferoxamine (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Deferoxamine 相关抗体:

    Western Blot Analysis[1]

    Cell Line: MEFs cells
    Concentration: 1 mM
    Incubation Time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
    Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.
    Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

    Western Blot Analysis[2]

    Cell Line: HepG2 cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Showed a twofold increase of InsR mRNA levels in cells.
    Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

    Cell Proliferation Assay[3]

    Cell Line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days (TAMSCs); 9 days (BMMSCs).
    Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose.

    Apoptosis Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days
    Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

    Western Blot Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 10 µM
    Incubation Time: 3 days
    Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

    Cell Autophagy Assay[4]

    Cell Line: SH-SY5Y cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.
    Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.
    体内研究
    (In Vivo)

    Deferoxamine (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice[1].
    Deferoxamine (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1].
    Dosage: 560.68 mg/per (10 uL of 1 mM)
    Administration: Drip-on; once daily for 21 days.
    Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
    Animal Model: Male Sprague-Dawley rats (180-200 g)[2].
    Dosage: 200 mg/kg
    Administration: Intraperitoneal injection; daily for 2 weeks.
    Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
    Clinical Trial
    分子量

    560.68

    Formula

    C25H48N6O8
    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    去铁胺
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 10 mg/mL (17.84 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.7835 mL 8.9177 mL 17.8355 mL
    5 mM 0.3567 mL 1.7835 mL 3.5671 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.25 mg/mL (2.23 mM); 澄清溶液

      此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.25 mg/mL (2.23 mM); 澄清溶液

      此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

      20% SBE-β-CD in Saline 的配制（4°C，储存一周）：2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.76%

    COA (184 KB) HNMR (284 KB) LCMS (89 KB)

    产品使用指南 (1538 KB)
    参考文献

    Deferoxamine 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7835 mL 8.9177 mL 17.8355 mL 44.5887 mL
    5 mM 0.3567 mL 1.7835 mL 3.5671 mL 8.9177 mL
    10 mM 0.1784 mL 0.8918 mL 1.7835 mL 4.4589 mL
    15 mM 0.1189 mL 0.5945 mL 1.1890 mL 2.9726 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Deferoxamine70-51-9Deferoxamine B Deferriferrioxamine B Deferrioxamine去铁胺HIF/HIF Prolyl-HydroxylaseReactive Oxygen SpeciesApoptosisAktAutophagyHypoxia-inducible factorsHIFsHIF-PHPKBProtein kinase Bdiabetes mellitusneovascularizationcancerAlzheimer’s diseaseMEFsTAMSCsBMMSCsCOVID-19PDSH-SY5YInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Deferoxamine
    目录号：
    HY-B1625
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z